Headquartered in Bangalore, Biocon Ltd, a leading Indian pharmaceutical company, is positioning itself in the weight loss drug market as patents for some blockbuster obesity medications are set to expire. The company has secured approval from the UK's regulatory authority for the first generic version of liraglutide, an injectable drug...
India’s Biocon Acquires Eywa Pharma of New Jersey
Bangalore headquartered biopharmaceutical company, Biocon Ltd., announced that its step-down, wholly-owned subsidiary, Biocon Generics Inc., has acquired Eywa Pharma Inc.’s oral solid dosage manufacturing facility, located in Cranbury, New Jersey, effective 1st September, 2023. The facility was acquired for a total consideration $7.7 million. As part of the acquisition, the...
Biocon Biologics Acquires Viatris’ Global Biosimilars Business
Biocon Biologics a subsidiary of Biocon Ltd., based in Bangalore, India, successfully completed its multi-billion dollar acquisition of the global biosimilars business of its partner Viatris Inc. headquartered in Canonsburg, Pennsylvania. Viatris received a $2 billion upfront cash payment and $1 billion in Compulsorily Convertible Preference Shares, representing a stake...
Biocon India Receives US FDA Approval for Biosimilar
India's Bangalore-based Biocon Ltd is the country's first company to have a "biosimilar" approved in the U.S. for Roche’s drug Trastuzumab, marketed as Herceptin, and used in treating certain breast and stomach cancers. Kiran Mazumdar-Shaw, the company’s chairperson and managing director said, "This was the first biosimilar for Herceptin approved...